Latest News

Early data from the Clinical Nurse Navigator program show that more than 99% of patients with Parkinson's disease reaching a first optimization dose of continuous subcutaneous apomorphine infusion did so without antiemetic pretreatment.

At ATMRD 2026, the director of Movement Disorders at Banner Sun Health Research Institute discussed emerging biomarker and imaging technologies, the importance of clinical diagnostic expertise, and the evolving treatment landscape for atypical parkinsonian disorders and adult-onset ataxias.

Here's some of what is coming soon to NeurologyLive® this week.

Real-world survey data suggest deutetrabenazine treatment may be associated with improvements in patient- and caregiver-reported quality-of-life outcomes among individuals with Huntington disease chorea.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Brain insulin resistance!

Exploratory post hoc data suggest prompt pimavanserin initiation within 6 to 12 months of PDP onset may yield a more favorable symptom trajectory, though prospective confirmation is needed.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 5, 2026.

Phase 2b PROCEED trial results and a phase 1 drug interaction study for bocunebart were presented at AHS 2026, collectively strengthening the drug's development case as a first-in-class PACAP-targeting therapy.

As the MS community reflects on World MS Day, Alla Wilson, a clinical ambulatory pharmacist at Shields Health Solutions, discusses how integrated specialty pharmacy models can improve treatment access, adherence, and patient-reported outcomes for multiple sclerosis.

The assistant professor of neurology at NYU Grossman School of Medicine discussed how optical coherence tomography can support the 2024 McDonald Criteria for multiple sclerosis at CMSC 2026.

12-montn interim findings from an ongoing phase 1/2 study showed up to 69% reductions in mutant huntingtin protein and favorable cUHDRS trends with the investigational oral RNA-splicing modifier SKY-0515.

Kyle Blackburn, MD, a neurologist at UT Southwestern Medical Center, discussed new proposed updates to the diagnostic criteria and nosology for myelitis presented at the 2026 CMSC Annual Meeting.

Updated clinical data highlight opakalim’s ongoing development in epilepsy, with pivotal focal epilepsy results expected later this year.